Participants who are required to permanently discontinue both study treatments are listed in Section 8.1 . In addition, all Grade 2 hepatic, pulmonary, renal, GI, and neurological AEs s hould be evaluated and managed per the toxicity management al gorithms ( Appendix 6 ). Participants not meeting guid elines for Revised Protocol No.: 04 Date: 31-May-2019 84 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS permanent discontinuation will be permitted to resume study treatment based on the criteria specified below in Section 8.1.1 . Participants eligible to resume study treatment will resume study treatment at the visit following their last received dose. In all cohorts, if there is a delay in dosing of BMS-986226 alone or in combination with nivolumab or ipilimumab, between 1 and 12 days, the procedures at the original scheduled visit should be performed as soon as possible. If the delay is more than 12 days, the visit and dose w ill be considered missed; the procedures at the next scheduled visit should be performed, and subsequent BMS-986226 doses will follow every 4 weeks. Extensions to the period of dose delays may be granted for individual participants on a case-by-case basis after specific consultation and agreement between the investigator and BMS Medical Monitor/Study Director (or designee) in settings where benefit/risk may justify continued study treatment (eg, par ticipant deriving clinical benefit who requires prolonged steroid taper for the management of non-DLT -drug-related- AEs or experiences delays for the management of a nondrug-related AE). The end of cycle tumor assessments (ie, CT/MRI, PET, etc) w ill continue on a Q8W schedule relative to the participant’s first dose re gardless of any study treatment delay incurred. 7.3.2 BMS-986226 Dose-limiting Toxicities For the purpose of guiding dose escalation, DLTs will be defined based on the incidence, intensity, and duration of AEs for which no clear alternative cause is identified. The DLT period will be 35 days (5 weeks). In the Preliminary Safety Cohorts, participants who have received 1 dose of BMS-986226 and have completed, or who discontinued due to a DLT in the 4-week DLT period, will be considered as DLT-evaluable participants for BMS-986226 monotherapy. In Part A, participants who have received 2 dos es of BMS-986226 and have completed, or who discontinued due to a DLT in the 5-week DLT period, will be considered as DLT-evaluable participants for BMS-986226 monotherapy. In Parts B, C, D and E, participants receiving ei ther 1 dose of BMS-986226 or 2 doses of either nivolumab or ipilimumab, or participants who discontinued due to a DLT in the 5-week combination treatment DLT period, w ill be considered as DLT-evaluable participants for combination treatment. Participants who wit hdraw from the study during the DLT evaluation period or have received less than 2 doses for reasons other than a DLT in the monotherapy (Part A) or 1 dose in combination therapy (Parts B, C, D, E), will not be considered as DLT-evaluable participants and may be replaced with a new parti cipant at the same dose level. Participants in Part A, who are dose delayed during the DLT evaluati on period for reasons other than a DLT could be considered as DLT-evaluable participants if they receive at least 2 doses of therapy. For the purpose of participant management, any A E that meets DLT criteria, regardless of the cycle in which it occurs, will lead to discontinuation of study tr eatment (except as defined in Section 7.3.5 ). Participants who withdraw from the study during the 5-week DLT evaluation period for reasons other than a DLT may be replaced with a new participant at the same dose Revised Protocol No.: 04 Date: 31-May-2019 85 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS level. The incidence of DLT(s) during the 5-week DLT evaluation period will be used in dose escalation d ecisions th rough application of the BLRM/BLRM- Copula model. AE s occurring after the DLT period will be considered to enhance the robustness of BLRM/BLRM-Copula prediction, upon agreement between the Sponsor, Medical Monitor/Study Director (or designee), and investigators. Participants experiencing a DLT will enter the safety follow-up period of the study. DLTs occurring after the 4-week DLT observation period for the Preliminary Safety C ohorts or 5-week DLT observation period for Parts A, B and C will be accounted for in determining the MAD for the combination part. AEs will be graded according to the NCI CTCAE v4.03 27, as listed below: A. Hepatic Non-hematological DLT Any one of the following study treatment-rela ted events will be considered a hepatic DLT: •Any Grade ≥3 elevation of AST, ALT, or total bilirubin. •Grade 2 AST or ALT with symptomatic liver inflammation (eg, right upper quadrant tenderness, jaundice, pruritus). •AST or ALT > 3× ULN and concurrent total b ilirubin > 2× ULN without initial findings of cholestasis (elevated serum alkaline phosphatase [A LP] [eg, findings consistent with Hy’s law or FDA definition of potential drug-induced liv er injury or potential drug-induced liver injury [p-DILI]). Note that this special category of D LT uses ULN rather than Common Toxicity Criteria (CTC) grade for definition.